SG Americas Securities’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-25,000
Closed -$34K 3417
2024
Q2
$34K Buy
+25,000
New +$3.76M ﹤0.01% 2731
2022
Q4
Sell
-150,000
Closed -$33K 3062
2022
Q3
$33K Buy
+150,000
New +$19M ﹤0.01% 3050

Other funds holding AZN

SG Americas Securities's AZN Position: Q1 2026 in Review

SG Americas Securities reduced its AstraZeneca (AZN) stake by 94% in Q1 2026, selling an estimated $22.9M and leaving 8,013 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

SG Americas Securities first reported a position in AZN in Q4 2016 and has held it in 34 quarters since. The position peaked at $23.3M in Q4 2025. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • SG Americas Securities held 8,013 shares of AstraZeneca worth $1.58M as of Q1 2026.
  • SG Americas Securities sold 118,724 AstraZeneca shares in Q1 2026, an estimated $22.9M.
  • AstraZeneca made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1506 holding.
  • SG Americas Securities first reported a position in AstraZeneca in Q4 2016 and has held it in 34 quarters since.
  • SG Americas Securities's AstraZeneca position peaked at $23.3M in Q4 2025.
  • 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.